We are focusing our established and pipeline medicines to treat and prevent life‑threatening conditions that significantly impact overall health, beginning with chronic kidney disease and obesity.
Chronic kidney disease, which affects nearly half of all people with type 2 diabetes, is associated with an increased risk of kidney failure and cardiovascular disease. With currently available care, treatment for end-stage kidney disease is limited to dialysis and kidney transplant, which are both costly and associated with short life expectancy. Despite this immense medical need, it has been two decades since a new treatment for diabetic kidney disease has been identified. Our goal is to change that in the near future. By exploring additional renal benefits of our established sodium-glucose cotransporter 2 (SGLT2) inhibitor, as well as several promising early pipeline drugs, we are moving closer each day to bringing new treatments to people living with chronic kidney disease.
Nearly 40 percent of adults in the U.S. and 13 percent of adults worldwide are obese. Obesity can lead to increased rates of cardiovascular disease, diabetes, nonalcoholic fatty liver disease and other life-threatening complications. That is why we are focused on finding effective weight reducing therapies for obese patients at the highest risk for disease.